Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 10/20 | 0.43 |
| ▸ | FLT4 | P35916 | 7/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524415 | 0.81 | CNR2 (0.48) | PTK2GSK3AGSK3BCDC7ROCK2 | |
| SCHEMBL15524495 | 0.79 | FLT4 (0.48) | PTK2FLT4KDRGSK3AGSK3B | |
| SCHEMBL15524738 | 0.78 | FLT4 (0.40) | FLT4KDR | |
| SCHEMBL15524830 | 0.78 | PTK2 (0.49) | PTK2FLT4KDR | |
| SCHEMBL15524693 | 0.77 | JAK3 (0.45) | PTK2GSK3AGSK3BFLT3 | |
| SCHEMBL12478740 | 0.77 | PTK2 (0.53) | PTK2 | |
| SCHEMBL12478690 | 0.77 | PTK2 (0.53) | PTK2GSK3AGSK3B | |
| SCHEMBL12478992 | 0.76 | PTK2 (0.51) | PTK2 | |
| SCHEMBL15524665 | 0.76 | GSK3A (0.40) | PTK2GSK3AGSK3BCDC7ROCK2 | |
| SCHEMBL12478260 | 0.76 | PTK2 (0.54) | PTK2FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885FLT4 617/4885KDR 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.